Zoetis Inc. $ZTS Stock Holdings Lifted by Cerity Partners LLC

Cerity Partners LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 32.0% during the second quarter, Holdings Channel reports. The firm owned 325,061 shares of the company’s stock after purchasing an additional 78,738 shares during the quarter. Cerity Partners LLC’s holdings in Zoetis were worth $50,693,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Savvy Advisors Inc. boosted its holdings in Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after purchasing an additional 1,114 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after buying an additional 152 shares during the period. Canoe Financial LP grew its position in Zoetis by 859.0% during the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after buying an additional 11,975 shares in the last quarter. Strs Ohio bought a new position in Zoetis during the first quarter valued at about $22,891,000. Finally, Chicago Partners Investment Group LLC increased its stake in Zoetis by 67.0% during the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock valued at $750,000 after acquiring an additional 1,961 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $118.69 on Monday. The firm has a market capitalization of $52.31 billion, a P/E ratio of 19.98, a P/E/G ratio of 2.46 and a beta of 0.97. The stock has a fifty day moving average price of $133.77 and a two-hundred day moving average price of $147.57. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the company earned $1.58 EPS. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st were paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend was Friday, October 31st. Zoetis’s dividend payout ratio is currently 33.67%.

Wall Street Analyst Weigh In

A number of analysts have commented on ZTS shares. JPMorgan Chase & Co. reduced their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Wednesday, December 3rd. Stifel Nicolaus dropped their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.